Q-omics provides the consensus-scored LRWD1 profile across patient tissues and cancer cell-line models. LRWD1 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, LRWD1 is differentially expressed in 16, with the highest sampling consensus in COAD. Additionally, LRWD1 protein abundance shows 25,373 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight UVM, COAD, and LSCC as cancer lineages where LRWD1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LRWD1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LRWD1 survival associations across molecular data types. LRWD1 RNA expression shows survival associations in the most cancer types (26), followed by mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LRWD1 RNA expression–survival associations across cancer types. High LRWD1 expression shows unfavorable associations in UVM, KICH, LGG, LIHC, ACC and KIRC. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for LRWD1 RNA expression.
This table summarizes LRWD1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16, while mass-spec protein shows differences in 5. The strongest signals are observed in COAD for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for LRWD1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LRWD1 shows higher tumor expression in COAD, BLCA, KIRP, HNSC, STAD and LUAD. The COAD box plot shows higher LRWD1 RNA expression in tumor versus normal tissue (log2 FC = +1.186, t-test p < 0.001).
This table shows molecular features associated with LRWD1 in patient tissues and cancer cell lines. In patient samples, LRWD1 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, LRWD1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in OESOPHAGUS and LUNG_SCLC.
